Connecting Hope and
Medical Science
    

      
 

CCRP Clinical Trials

Click here for Physician Area

Only show trials for the disease site :

DiseaseSiteProtocolNumberStatusTitle
BoneS0702 (CTSU/SWOG)CLOSED TO ACCRUALA Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid treatment.
BrainN0872CLOSED TO ACCRUALPhase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma.
BrainN107C (CTSU/NCCTG)OPENA Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease.
BrainE3F05SUSPENDEDPhase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas.
BrainN0577 (CTSU/NCCTG)OPENPhase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma.
BreastBO25126CLOSED TO ACCRUALA Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer. (APHINITY)- BIG 4-11/BO25126/TOC4939G)
BreastFB-7 (NSABP FRP)OPENA Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer.
BreastE5103CLOSED TO ACCRUALA Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer.
BreastB-42CLOSED TO ACCRUALA Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer.
BreastE3108SUSPENDEDA Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen.
12345678910...